Many investors may never have heard of AngioDynamics (NASDAQ: ANGO) , which produces "minimally invasive medical devices" to treat peripheral vascular disease and cancer, according to its website.
Some, however, may have taken notice after the July 13 announcement of net sales for the fourth quarter of 2021 (which ended May 31). A top line of $76.8 million was comfortably higher than the analyst consensus of $72.7 million and represented a 31.7% year-over-year surge over $58.3 million in Q4 2020.
Lest the investor community assume that this net sales beat was unsustainable, President and CEO Jim Clemmer pointed out in the earnings call that Q4 revenue represented an 8% rise over the third quarter.
For further details see:
After Beating Estimates, Is This Little-Known Medical Device Company a Buy?